Laboratory Corporation of America Holdings (Labcorp) has reported a 2.48% decline in revenue from the prior-year quarter and a substantial year-over-year earnings decrease of 33.22%. Despite these challenges, the company is strengthening its foothold by announcing a quarterly dividend of $0.72 per share and expanding operations through an agreement with Prisma Health to acquire select assets. Labcorp also maintains a significant capacity for COVID-19 testing, with the ability to conduct 250,000 PCR tests daily, while attracting interest from 60 hedge funds holding stakes worth approximately $2.9 billion.
“Laboratory Corporation of America Holdings (NYSE:LH) · is an independent clinical laboratory firm”
“Laboratory Corporation of America Holdings (NYSE:LH) · is earning · a lot on COVID-19 PCR tests”
“Laboratory Corporation of America Holdings (NYSE:LH) · has the ability to do · 250,000 COVID-19 PCR tests daily”
“Laboratory Corporation of America Holdings (NYSE:LH) · is an · independent clinical laboratory firm”
“Laboratory Corporation of America Holdings (NYSE:LH) · entered into an agreement · with Prisma Health · to acquire select assets”
“Laboratory Corporation of America Holdings (NYSE:LH) · had · number of hedge fund holders · 60”
“Laboratory Corporation of America Holdings (NYSE:LH) · is · an independent clinical laboratory firm”
“Laboratory Corporation of America Holdings (NYSE:LH) · has · a PE Ratio · 10.83”
“Laboratory Corporation of America Holdings (NYSE:LH) · is able to do · 250,000 COVID-19 PCR tests daily”
“Laboratory Corporation of America Holdings · has an ROCE of · 20% · 20%”
“Laboratory Corporation of America Holdings · is employing · 42% more capital · 42%”
“Laboratory Corporation of America Holdings · awarded · 91% · 91%”
